Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

peripheral T-cell lymphoma, not otherwise specified (PTCL) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

peripheral T-cell lymphoma, not otherwise specified

MONDO:0004964

Also known as:PTCL

Find Clinical TrialsTrials

Overview

Aggressive nodal or extranodal mature (peripheral) T-cell lymphomas that do not belong to the better defined entities of the remainder of mature T-cell lymphomas. This category includes the following variants: lymphoepithelioid cell variant (Lennert's lymphoma), follicular variant, and T-zone variant.

TreatmentsNo approved treatments · 6 in pipeline

Clinical Trials64 registered · 38 recruiting

Diagnosis

Biomarker and diagnostic research for peripheral T-cell lymphoma, not otherwise specified has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for peripheral T-cell lymphoma, not otherwise specified. An additional 6 compounds hold orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for peripheral T-cell lymphoma, not otherwise specified, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for peripheral T-cell lymphoma, not otherwise specified. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

64 clinical trials registered, 38 recruiting. Interventions under study include drug therapy, other interventions, biologic therapy, and procedural interventions. Pipeline includes 6 PHASE3, 17 PHASE2, 26 PHASE1. Research is sponsored by a mix of industry and academic institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT01137825](https://clinicaltrials.gov/study/NCT01137825)

Data assembled from 4 of 12 sources · Last updated Oct 3, 2026, 6:00 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

Questions for Your Care Team

→Are any of the 64 active clinical trials a good fit for my situation?
→With 6 compounds in the orphan drug pipeline, which are furthest along in development and which clinical trials should I be aware of?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Patient case studies	40	42%
Research summaries	16	17%
Disease patterns and progression	16	17%
Testing and diagnosis research	9	9%
Clinical study results	7	7%
Laboratory research	4	4%
Other research	2	2%
New treatment approaches	2	2%

peripheral T-cell lymphoma, not otherwise specified

Overview

Diagnosis

Treatment

Orphan Drug Designations

Research Landscape

Medical References

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications